Go Pro
NASDAQ:DTIL

Precision BioSciences Q4 2024 Earnings Report

Precision BioSciences logo
$6.33 +0.07 (+1.12%)
Closing price 10/1/2026 04:00 PM Eastern
Extended Trading
$6.30 -0.03 (-0.47%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precision BioSciences EPS Results

Actual EPS
-$3.20
Consensus EPS
-$2.09
Beat/Miss
Missed by -$1.11
One Year Ago EPS
N/A

Precision BioSciences Revenue Results

Actual Revenue
$3.47 million
Expected Revenue
$4.28 million
Beat/Miss
Missed by -$804.00 thousand
YoY Revenue Growth
N/A

Precision BioSciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 26, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Precision BioSciences' Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Precision BioSciences Earnings Headlines

MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel
Precision Biosciences Inc.
Precision BioSciences: Promising HBV Editing Evidence
See More Precision BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email.

About Precision BioSciences

Precision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing medicines for genetically driven diseases. The company’s platform, ARCUS, uses engineered homing endonucleases designed to make precise changes to DNA, including targeted gene insertion, deletion and correction.

Precision’s pipeline has included in vivo gene-editing programs intended to address conditions such as Duchenne muscular dystrophy and chronic hepatitis B. The company has also developed allogeneic CAR T-cell candidates and has pursued collaborations and licensing arrangements to advance its gene-editing technology across therapeutic applications.

Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences conducts research and clinical development through operations and partnerships that support the development of genetic medicines in the United States and internationally.

View Precision BioSciences Profile